Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVT NASDAQ:LEGN NASDAQ:PTCT NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$35.34+1.8%$30.02$14.32▼$36.28$7.13B0.761.60 million shs3.89 million shsLEGNLegend Biotech$27.93-16.7%$27.47$16.24▼$45.30$6.23B0.352.70 million shs13.60 million shsPTCTPTC Therapeutics$78.98+0.6%$71.21$43.17▼$87.50$6.51B0.561.61 million shs2.86 million shsQUREuniQure$46.29-3.9%$24.13$8.73▼$71.50$3.04B0.982.20 million shs4.85 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+3.27%+11.32%+30.83%+46.77%+126.71%LEGNLegend Biotech+0.42%-3.84%+24.24%+87.58%-3.40%PTCTPTC Therapeutics+7.18%+7.06%+11.95%+17.09%+54.43%QUREuniQure+78.44%+79.57%+93.18%+215.60%+225.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$35.34+1.8%$30.02$14.32▼$36.28$7.13B0.761.60 million shs3.89 million shsLEGNLegend Biotech$27.93-16.7%$27.47$16.24▼$45.30$6.23B0.352.70 million shs13.60 million shsPTCTPTC Therapeutics$78.98+0.6%$71.21$43.17▼$87.50$6.51B0.561.61 million shs2.86 million shsQUREuniQure$46.29-3.9%$24.13$8.73▼$71.50$3.04B0.982.20 million shs4.85 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+3.27%+11.32%+30.83%+46.77%+126.71%LEGNLegend Biotech+0.42%-3.84%+24.24%+87.58%-3.40%PTCTPTC Therapeutics+7.18%+7.06%+11.95%+17.09%+54.43%QUREuniQure+78.44%+79.57%+93.18%+215.60%+225.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.45Hold$37.335.64% UpsideLEGNLegend Biotech 2.67Moderate Buy$60.23115.65% UpsidePTCTPTC Therapeutics 2.71Moderate Buy$91.3615.67% UpsideQUREuniQure 2.65Moderate Buy$58.9227.28% UpsideCurrent Analyst Ratings BreakdownLatest QURE, IMVT, LEGN, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026QUREuniQure Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $65.006/18/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/18/2026QUREuniQure Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $70.006/18/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$14.00 ➝ $46.006/18/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$25.00 ➝ $65.006/17/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingPositive6/17/2026QUREuniQure Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$61.006/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.006/3/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026LEGNLegend Biotech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $49.006/3/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $65.00(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/ALEGNLegend Biotech$1.03B5.04N/AN/A$5.43 per share5.14PTCTPTC Therapeutics$1.73B3.79$8.82 per share8.95($2.56) per share-30.85QUREuniQure$16.10M181.34N/AN/A$3.19 per share14.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.68N/A15.43N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A37.433.61-22.58%-362.45%-6.76%8/6/2026 (Estimated)QUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%8/4/2026 (Estimated)Latest QURE, IMVT, LEGN, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/13/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A9.099.09LEGNLegend BiotechN/A2.132.05PTCTPTC TherapeuticsN/A2.442.36QUREuniQure0.3310.4010.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%LEGNLegend Biotech70.89%PTCTPTC TherapeuticsN/AQUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant1.80%LEGNLegend Biotech0.02%PTCTPTC Therapeutics5.50%QUREuniQure4.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120205.31 million201.61 millionOptionableLEGNLegend Biotech2,965185.74 million185.70 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableQUREuniQure50063.07 million60.13 millionOptionableQURE, IMVT, LEGN, and PTCT HeadlinesRecent News About These CompaniesThe Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-13031 minutes ago | en.hdbuzz.netEuniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy4 hours ago | benzinga.comUniQure (QURE) Soars 78% on AMT-130 ProgressJune 18 at 6:03 PM | finance.yahoo.comUniQure to seek approval for Huntington's therapy after FDA U-turn, shares skyrocketJune 18 at 6:03 PM | msn.comuniQure Stock Looks Drastically Undervalued After Upbeat FDA MeetingJune 18 at 1:51 PM | barchart.comUniQure: AMT-130's FDA Path Reaffirms My Bull CaseJune 18 at 10:06 AM | seekingalpha.comuniQure (NASDAQ:QURE) Upgraded to Overweight at BarclaysJune 18 at 9:02 AM | marketbeat.comuniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?June 18 at 8:31 AM | zacks.comuniQure (NASDAQ:QURE) Insider Jeannette Potts Sells 5,237 SharesJune 18 at 8:13 AM | insidertrades.comEversept Partners LP Has $1.50 Million Stock Holdings in uniQure N.V. $QUREJune 18 at 5:45 AM | marketbeat.comClearline Capital LP Takes Position in uniQure N.V. $QUREJune 18 at 5:09 AM | marketbeat.comArtia Global Partners LP Boosts Stake in uniQure N.V. $QUREJune 18 at 4:24 AM | marketbeat.comuniQure N.V. (NASDAQ:QURE) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 18 at 2:09 AM | americanbankingnews.comuniQure N.V. (NASDAQ:QURE) Given Average Recommendation of "Moderate Buy" by AnalystsJune 18 at 2:07 AM | marketbeat.comuniQure (NASDAQ:QURE) Director Sells 10,000 SharesJune 17 at 7:05 PM | marketbeat.comuniQure (NASDAQ:QURE) Insider Jeannette Potts Sells 5,237 SharesJune 17 at 5:28 PM | marketbeat.comThis Biotech Stock Is Surging 73% on Surprise Good News From FDAJune 17 at 5:01 PM | msn.comuniQure sets course to US filing for Huntington gene therapyJune 17 at 5:01 PM | pharmaphorum.comPuniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s DiseaseJune 17 at 5:01 PM | markets.businessinsider.comuniQure soars as Cantor upgrades on plans to seek gene therapy nodJune 17 at 5:01 PM | seekingalpha.comUniQure stock surges after FDA U-turn clears path to gene therapy filingJune 17 at 5:01 PM | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQURE, IMVT, LEGN, and PTCT Company DescriptionsImmunovant NASDAQ:IMVT$35.34 +0.63 (+1.82%) Closing price 04:00 PM EasternExtended Trading$35.34 -0.01 (-0.01%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Legend Biotech NASDAQ:LEGN$27.93 -5.59 (-16.68%) Closing price 04:00 PM EasternExtended Trading$28.23 +0.30 (+1.07%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.PTC Therapeutics NASDAQ:PTCT$78.98 +0.45 (+0.57%) Closing price 04:00 PM EasternExtended Trading$78.91 -0.07 (-0.09%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.uniQure NASDAQ:QURE$46.29 -1.87 (-3.88%) Closing price 04:00 PM EasternExtended Trading$46.52 +0.23 (+0.50%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
